Preparation and characterization of gemcitabine liposome injections

Pharmazie

Volumn 67, Issue 10, 2012, Pages 844-847

  Zhou, Qinmei ^a   Liu, Liucheng ^a   Zhang, Dengshan ^a   Fan, Xingfeng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; LIPOSOME;

ARTICLE; DRUG ANALYSIS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; DRUG TUMOR LEVEL; EMULSION; FILTRATION; LIPOSOMAL DELIVERY; PARTICLE SIZE; QUALITY CONTROL; REPRODUCIBILITY; TEMPERATURE; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL;

EID: 84868293669     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1157     Document Type: Article

References (14)

1. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raberet MN (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-498.
2. Celano M, Calvagno MG, Bulotta S, Paolino D, Arturi F, Rotiroti D, Filetti S, Fresta M, Russo D (2004) Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells. BMC Cancer 4: 63-70.
3. Dasanu CA (2008) Gemcitabine vascular toxicity and prothrombotic potential. Expert Opin Drug Saf 7: 703-716.
4. Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK (1997) Maximum-tolerated dose defined for single-agent gemcitabine. A phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 15: 310-316. (Pubitemid 27020589)
5. Laouini A, Jaafar-Maalej C, Sfar S, Charcosset C, Fessi H (2011) Liposome preparation using a hollow fiber membrance contactor - Application to spironolactone encapsulation. Int J Pharm 415: 53-61.
6. Lichtenberg D, Barenholz Y (1988) Liposomes: preparation, characterization, and preservation. Methods Biochem 33: 337-462.
7. Ranson MR, Cheeseman S, White S, Margison J (2001) Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer. Crit Rev Oncol Hematol 37: 115-120. (Pubitemid 32106910)
8. Reddy LH, Couvreur P (2008) Novel approaches to deliver gemcitabine to cancers. Curr Pharm 14: 1124-1137. (Pubitemid 351982559)
9. Rossi C, Fardella G, Chiappini I, Perioli L, Vescovi C, Ricci M, Giovagnoli S, Scuota S (2004) UV spectroscopy and reverse-phase HPLC as novel methods to determine Capreomycin of liposomal formulations. J Pharm Biomed Anal 36: 249-255. (Pubitemid 39371069)
10. Stathis A, Moore ML (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7: 163-172.
11. Storniolo AM, Allerheiligen SRB, Pearce HL (1997). Preclinical, pharmacologic, and phase I studies of gemcitabine. Semin Oncol 242 suppl 7 2-7.
12. Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F (2005) Role of gemcitabine in cancer therapy. Future Oncol 1: 7-17.
13. Woodle MC, Newman MS, Martin FJ (1992) Liposome, leakage and blood circulation: Comparison of adsorbed block copolymers with covalent attachment of PEG. Int J Pharm 88: 327-334. (Pubitemid 23000436)
14. Yu X, Zhang Y, Chen C, Yao Q, Li M (2010) Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta 1805: 97-104.